News & Media

Take a look inside our world

Press Releases

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatme...

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deute...

Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabe

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophr...

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of ...

Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Mi

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Sympto...

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Our People Working at Teva Patient Focus Social Impact Environment Leadership Quality ESG Generic Medicines Research and Development Diversity and inclusion Biopharm Global Operations Wellbeing Medicine Safety Teva api Innovation R&D Health & Technology Economic Impact

Meet Yuliana Katsarska: Leading Medicines Packaging for Patients

Meet Yuliana Katsarska: Leading Medicines Packaging for Patients

“Mental health care is not a one stop deal": How Teva is Combining Medicine and Ongoing Support

“Mental health care is not a one stop deal": How Teva is Combining Medicine and Ongoing Support

Why Diversity in Clinical Trials is So Important

Why Diversity in Clinical Trials is So Important

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Mental Health Moments: Breaking Barriers

Mental Health Moments: Breaking Barriers

3 Trends I’m Watching in Patient Safety

3 Trends I’m Watching in Patient Safety

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Migraine at Work: How it Impacts Us All

Migraine at Work: How it Impacts Us All

Addressing Antimicrobial Resistance

Addressing Antimicrobial Resistance
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more